SCHEMBL8284972

SCHEMBL8284972

CC(C)(C)[C@H](N=C=O)C(=O)OCc1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.47
SLC6A2 P23975 1/20 0.46
SLC6A3 Q01959 1/20 0.46
KMT2A Q03164 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.43
MAPK1 P28482 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
CTSS P25774 3/20 0.42
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
CTSB P07858 3/20 0.41
CTSL P07711 2/20 0.41
CTSK P43235 1/20 0.40
LMNA P02545 1/20 0.40
HCAR2 Q8TDS4 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6963343 0.81 ALDH1A1 (0.49) ALDH1A1SLC6A2SLC6A3KMT2ATDP1
SCHEMBL12935748 0.81 ALDH1A1 (0.49) ALDH1A1SLC6A2SLC6A3KMT2ATDP1
SCHEMBL23696190 0.80 ALDH1A1 (0.51) ALDH1A1SLC6A2SLC6A3KMT2ATDP1
SCHEMBL10831915 0.80 ALDH1A1 (0.51) ALDH1A1SLC6A2SLC6A3KMT2ATDP1
SCHEMBL8610837 0.80 CTSS (0.47) ALDH1A1SLC6A2SLC6A3KMT2ATDP1
SCHEMBL8610832 0.80 CTSS (0.47) ALDH1A1SLC6A2SLC6A3KMT2ATDP1
SCHEMBL6946124 0.79 ALDH1A1 (0.62) ALDH1A1SLC6A2SLC6A3KMT2ATDP1
SCHEMBL14074312 0.79 CES1 (0.40) ALDH1A1KMT2A
SCHEMBL8789734 0.78 ALDH1A1 (0.39) ALDH1A1KMT2ASMN1; SMN2MAPK1L3MBTL1
SCHEMBL9171291 0.78 ALDH1A1 (0.40) ALDH1A1KMT2ASMN1; SMN2L3MBTL1CTSS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7423058-B2 Inhibitors of hepatitis C virus NS3 protease SCHERING CORPORATION (US) 2008-09-09 US disclosed
US-7423058-B2 Inhibitors of hepatitis C virus NS3 protease SCHERING CORPORATION (US) 2008-09-09 US disclosed
US-20070142301-A1 Novel inhibitors of Hepatitis C virus NS3 protease MERCK SHARP & DOHME CORP. 2007-06-21 US disclosed
US-20070142301-A1 Novel inhibitors of Hepatitis C virus NS3 protease MERCK SHARP & DOHME CORP. 2007-06-21 US disclosed
US-7205330-B2 Inhibitors of hepatitis C virus NS3 protease SCHERING CORPORATION (US) 2007-04-17 US disclosed
US-7205330-B2 Inhibitors of hepatitis C virus NS3 protease SCHERING CORPORATION (US) 2007-04-17 US disclosed
WO-2005085275-A1 INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE SCHERING CORPORATION (US) 2005-09-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070142301-A1 Novel inhibitors of Hepatitis C virus NS3 protease HAVCR2, RNASE1, SERPINB1 ALDH1A1 1005/4885SLC6A2 4568/4885SLC6A3 3814/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.